Published in Angiogenesis Weekly, September 5th, 2008
"We demonstrated the marked inhibitory activity of enzastaurin against GEO colon and PC3 prostate cancer cells and their gefitinib-resistant counterparts GEO-GR and PC3-GR, accompanied by inhibition of pAkt and its effector pp70S6K, pGSK3...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Angiogenesis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.